CJ Bioscience
311690
企业摘要
季度业绩走势
营业收入
营业利润率
市场偏好度
※ 点击图表可查看该月份的AI分析信息。
营业收入
合并
单独
营业利润
合并
单独
净利润
合并
单独
财务信息
保存为Excel
该期间没有财务信息数据。
~
季度
决算
*单位基准小数点第四位以下的数值标记为'0/-0'
财务指标预测
※ 本预测值是基于历史数据的AI简单估算值，可能与实际业绩存在差异。
企业概况
截至2026年6月
CJ Bioscience declared its '2024 New Vision' statement, under which it has adopted the vision of becoming 'A Global Innovator in Healthcare through AI-powered Microbiome Science' with competitiveness in the global market by consolidating AI-based R&D technology and capabilities. In its (1) microbiome therapeutics (new drug development) business, CJRB-101, a new drug candidate independently discovered and isolated from fermented food, has shown preclinical data demonstrating a tumor growth-inhibiting effect against lung cancer, and has received IND approval for Phase 1/2 clinical trials from the US FDA (January 20, 2023) and from Korea's MFDS, the Ministry of Food and Drug Safety (June 15, 2023); clinical trials are ongoing in the United States and Korea, with the first patient dosed in Korea in October 2023.
代表理事
Yoon Sangbae
成立日期
2009年11月18日
法人类型
韩国创业板
行业分类
Research and experimental development on natural sciences and engineering
法人注册号
11011-4222503
营业执照号
119-86-23145
电话号码
02-6078-3456
传真号码
02-6078-3457
公司地址
14 Sejong-daero, Jung-gu, Seoul
产品与服务
评论